Diagnosis & Disease Information

FDA Approves First-In-Class Antibiotic to Treat Community-Acquired Bacterial Pneumonia

The FDA has approved Xenleta (lefamulin; Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.

Antibiotics

Treatment Options for Methicillin-Resistant Staphylococcus Aureus Pneumonia Evaluated

Evidence for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia with trimethoprim-sulfamethoxazole (TMP-SMX), clindamycin, doxycycline, or minocycline was found to be based on limited data, according to a systematic review published in the Annals of Pharmacotherapy. Currently, the Infectious Disease Society of America (IDSA) recommends vancomycin and linezolid for the treatment of MRSA pneumonia, although…